Delivery patterns of recommended chronic kidney disease care in clinical practice: Administrative claims-based analysis and systematic literature review

Clinical and Experimental Nephrology

Volumn 12, Issue 1, 2008, Pages 41-52

  Philipneri, Marie D ^a   Rocca Rey, Lisa A ^a,b   Schnitzler, Mark A ^a   Abbott, Kevin C ^c   Brennan, Daniel C ^d   Takemoto, Steven K ^a   Buchanan, Paula M ^a   Burroughs, Thomas E ^a   Willoughby, Lisa M ^a   Lentine, Krista L ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Chronic kidney disease; Guideline adherence; Laboratory diagnoses; Physician's practice patterns; Referral and consultation

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PARATHYROID HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEALTH CARE; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; CREATININE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHROLOGY; PARATHYROID HORMONE; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 38549095675     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0016-3     Document Type: Article

References (56)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1-12.
2. Healthy People 2010 obtained from http://www.healthypeople.gov/about/ hpfact.htm.
3. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Inter Med. 2005;142(5):342-51.
4. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-64.
5. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Inter Med. 2003;139(4):244-52.
6. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12(7):1501-7.
7. Winkelmayer WC, Levin R, Avorn J. The nephrologist's role in the management of calcium-phosphorus metabolism in patients with chronic kidney disease. Kidney Int. 2003;63(5):1836-42.
8. Lafayette RA, Lai G. Examining chronic kidney disease management in a single center. Clin Nephrol. 2004;62(4):260-6.
9. Kausz AT, Guo H, Pereira BJ, Collins AJ, Gilbertson DT. General medical care among patients with chronic kidney disease: opportunities for improving outcomes. J Am Soc Nephrol. 2005;16(10):3092-101.
10. Murray BM, Malireddi K, Vavilala V. Delivery of predialysis care in an academic referral nephrology practice. Ren Fail. 2005;27(5):571-80.
11. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
12. Avorn J, Bohn RL, Levy E, Levin R, Owen WF Jr, Winkelmayer WC, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Inter Med. 2002;162(17):2002-6.
13. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Inter Med. 2002;137(6):479-86.
14. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31(3):398-417.
15. De Nicola L, Minutolo R, Chiodini P, Zoccali C, Castellino P, Donadio C, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006;69(3):538-45.
16. Israni A, Korzelius C, Townsend R, Mesler D. Management of chronic kidney disease in an academic primary care clinic. Am J Nephrol. 2003;23(1):47-54.
17. Lenz O, Mekala DP, Patel DV, Fornini A, Metz D, Roth D. Barriers to successful care for chronic kidney disease. BMC Nephrology. 2005;6:11.
18. Saelen MG, Prosch LK, Gudmundsdottir H, Dyrbekk D, Helge Hunderi O, Arnesen E, et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Press. 2005;14(3):170-6.
19. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.
20. Kidney Disease Outcomes Quality Initiative G. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):I-IV.
21. de Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22(3):234-41.
22. Stevens LA, Fares G, Fleming J, Martin D, Murthy K, Qiu J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2439-48.
23. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Blood pressure and angiotensin converting enzyme inhibitor use in hypertensive patients with chronic renal insufficiency. (see comment). Am J Hypertens. 2001;14(12):1219-25.
24. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001;38(6):1398-407.
25. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol. 2001;12(8):1713-20.
26. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37(3):484-9.
27. Cleveland DR, Jindal KK, Hirsch DJ, Kiberd BA. Quality of prereferral care in patients with chronic renal insufficiency. Am J Kidney Dis. 2002;40(1):30-6.
28. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762-9.
29. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002;62(1):229-36.
30. London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002;40(3):539-48.
31. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant. 2002;17(8):1426-33.
32. London R, Solis A, Goldberg GA, Wade S, Chan WW. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manage Care Pharm. 2003;9(3):248-55.
33. Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, et al. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. Semin Dial. 2003;16(6):418-23.
34. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am College Cardiol. 2004;44(8):1587-92.
35. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. (see comment). Circulation. 2004;109(8):1004-9.
36. Rosen AB, Karter AJ, Liu JY, Selby JV, Schneider EC. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Inter Med. 2004;19(6):669-75.
37. So WY, Ozaki R, Chan NN, Tong PC, Ho CS, Lam CW, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension. 2004;44(3):294-9.
38. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrol Dial Transplant. 2005;20(6):1110-5.
39. De Nicola L, Minutolo R, Zamboli P, Cestaro R, Marzano L, Giannattasio P, et al. Italian audit on therapy of hypertension in chronic kidney disease: the TABLE-CKD study. Semin Nephrol. 2005;25(6):425-30.
40. Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. Progression of kidney disease in type 2 diabetes-beyond blood pressure control: an observational study. BMC Nephrol. 2005;6(1):8.
41. Minutolo R, De Nicola L, Zamboli P, Chiodini P, Signoriello G, Toderico C, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis. 2005;46(1):18-25.
42. Thanamayooran S, Rose C, Hirsch DJ. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant. 2005;20(11):2385-93.
43. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46(6):1080-7.
44. Jayapaul MK, Messersmith R, Bennett-Jones DN, Mead PA, Large DM. The joint diabetic-renal clinic in clinical practice: 10 years of data from a District General Hospital. Qjm. 2006;99(3):153-60.
45. Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis. 2006;47(1):103-14.
46. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Inter Med. 2006;166(17):1884-91.
47. Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant. 2006;21:2133-43.
48. National Cholesterol Education Program (NCEP) and Adult treatment Program III (ATP III) guidelines available at http://www.nhlbi.nih.gov/guidelines/ cholesterol/index.htm.
49. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification, referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48(2):192-204.
50. Lea JP, McClellan WM, Melcher C, Gladstone E, Hostetter T. CKD risk factors reported by primary care physicians: do guidelines make a difference? Am J Kidney Dis. 2006;47(1):72-7.
51. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Inter Med. 2005;165(14):1637-42.
52. Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28(1):59-64.
53. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351(13):1296-305.
54. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Inter Med. 2002;162(20):2269-76.
55. Stirnemann PM, Takemoto SK, Schnitzler MA, Brennan DC, Abbott KC, Salvalaggio P, et al. Agreement of immunosuppression regimens described in Medicare pharmacy claims with the Organ Procurement and Transplantation Network survey. J Am Soc Nephrol. 2006;17(8):2299-306.
56. Income, Poverty, and Health Insurance Coverage in the United States:2005. Obtained from US Census Bureau website (http://www.census.gov).